Literature DB >> 9121155

Survival benefit of extended D2 resection for proximal gastric cancer.

C M Volpe1, D L Driscoll, S M Miloro, H O Douglass.   

Abstract

BACKGROUND: The long-term survival of patients with adenocarcinoma of the proximal stomach remains dismal. Despite its increasing frequency and poor prognosis, a general consensus has not been reached on the extent of surgical resection. The significance of extended lymph node dissection (D2 gastrectomy) for the surgical treatment of patients with proximal gastric cancer was evaluated.
METHODS: Sixty-two patients who underwent a potentially curative total or proximal gastric resection were retrospectively divided by extent of lymphadenectomy into two groups: the extended resection group (D2,D2.5) and limited resection group (D1,D1.5). Survival rates were estimated by the method of Kaplan and Meier [J Am Stat Assoc 53:457-486, 1958] and the differences compared by the log rank test. Multivariate analysis of prognostic parameters was performed using the Cox proportional hazard model.
RESULTS: The median overall survival time for the extended resection group (D2,D2.5) was 34 months compared to 18 months for patients treated by a more limited resection (D1,D1.5). Patients treated with extended resection had an estimated 5-year overall survival rate of 37% compared to 21% for patients treated with limited resection. This difference was statistically significant with a P value of 0.04. The median disease-free interval for the extended resection group was 31 months compared to 17.6 months for patients in the limited resection group. The 5 year disease-free survival rate for both groups was 37% and 17%, respectively (P = 0.09). Extent of lymphadenectomy and stage of disease were found to be independent predictors of overall and cancer-free survival.
CONCLUSIONS: Patients treated with an extended lymph node dissection (D2 gastrectomy) were more likely to survive 5 years, had longer disease-free intervals, and prolonged median survival times (particularly patients with T1-3,N0-1,M0 cancers) as compared to those patients treated with a more limited lymph node dissection (D1,D1.5). These differences reached or approached statistical significance.

Entities:  

Mesh:

Year:  1997        PMID: 9121155     DOI: 10.1002/(sici)1096-9098(199703)64:3<231::aid-jso10>3.0.co;2-7

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  Risk factors related to operative morbidity in patients undergoing gastrectomy for gastric cancer.

Authors:  A Gil-Rendo; J L Hernández-Lizoain; F Martínez-Regueira; A Sierra Martínez; F Rotellar Sastre; M Cervera Delgado; V Valentí Azcarate; C Pastor Idoate; J Alvarez-Cienfuegos
Journal:  Clin Transl Oncol       Date:  2006-05       Impact factor: 3.405

2.  Prognostic impact of metastatic lymph node ratio in advanced gastric cancer from cardia and fundus.

Authors:  Chang-Ming Huang; Bi-Juan Lin; Hui-Shan Lu; Xiang-Fu Zhang; Ping Li; Jian-Wei Xie
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

Review 3.  Systematic review of D2 lymphadenectomy versus D2 with para-aortic nodal dissection for advanced gastric cancer.

Authors:  Zhen Wang; Jun-Qiang Chen; Yun-Fei Cao
Journal:  World J Gastroenterol       Date:  2010-03-07       Impact factor: 5.742

4.  D3 lymph node dissection in gastric cancer: evaluation of postoperative mortality and complications.

Authors:  K Günther; T Horbach; S Merkel; M Meyer; U Schnell; P Klein; W Hohenberger
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

5.  Surgical outcomes for gastric cancer in the upper third of the stomach.

Authors:  Jong Han Kim; Sung Soo Park; Jin Kim; Yoon Jung Boo; Seung Joo Kim; Young Jae Mok; Chong Suk Kim
Journal:  World J Surg       Date:  2006-10       Impact factor: 3.352

6.  Vagina vasorum dissection during D2 lymphadenectomy for gastric carcinoma.

Authors:  Jian-Jun Peng; Yu-Long He; Wen-Hua Zhan; Ping Xiao; Shi-Rong Cai; Chang-Hua Zhang; Hui Wu
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.